Trevi Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Trevi Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q3 2024.
  • Trevi Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 11 %, a 2.15% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 11 +0.23 +2.15% Sep 30, 2024
Q2 2024 8.69 -4.44 -33.8% Jun 30, 2024
Q1 2024 7.44 -10.8 -59.3% Mar 31, 2024
Q4 2023 9.08 -16.9 -65% Dec 31, 2023
Q3 2023 10.7 -30 -73.7% Sep 30, 2023
Q2 2023 13.1 -69.8 -84.2% Jun 30, 2023
Q1 2023 18.3 -128 -87.5% Mar 31, 2023
Q4 2022 26 -91.7 -77.9% Dec 31, 2022
Q3 2022 40.8 -60 -59.5% Sep 30, 2022
Q2 2022 82.9 Jun 30, 2022
Q1 2022 146 Mar 31, 2022
Q4 2021 118 Dec 31, 2021
Q3 2021 101 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.